Streetbeat News

Analyst Ratings

ZNTL

Stifel analyst Bradley Canino has maintained a 'Buy' rating on Zentalis Pharma (NASDAQ:ZNTL), but lowered the price target from $44 to $36.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:16 pm

GD

General Dynamics's (NYSE:GD) short percent of float has risen 25.29% since its last report, with 2.64 million shares sold short, which is 1.09% of all regular shares available for trading. It would take traders 1.76 days to cover their short positions on average. The company has less short interest than most of its peers, with the peer group average at 2.67%.

Portfolio Pulse from Benzinga Insights

November 07, 2023 | 3:15 pm

IQV

IQVIA Hldgs's (NYSE:IQV) short percent of float has risen 12.9% since its last report, with 3.93 million shares sold short, which is 2.45% of all regular shares available for trading. It would take traders 3.71 days to cover their short positions on average. The company's short interest is less than its peer group average of 5.37%.

Portfolio Pulse from Benzinga Insights

November 07, 2023 | 3:15 pm

AXP

American Express's (NYSE:AXP) short percent of float has risen 3.67% since its last report, with 6.51 million shares sold short, which is 1.13% of all regular shares available for trading. This increase in short interest can signal that investors have become more bearish. However, compared to its peers, American Express has less short interest as a percentage of float, with an average of 8.22%.

Portfolio Pulse from Benzinga Insights

November 07, 2023 | 3:15 pm

VRTX

Stifel analyst Paul Matteis maintains a 'Hold' rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raises the price target from $340 to $373.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:14 pm

THS

Stifel analyst Matthew Smith maintains a 'Hold' rating on Treehouse Foods (NYSE:THS) and lowers the price target from $47 to $42.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:13 pm

TGLS

Stifel analyst Stanley Elliott maintains a Buy rating on Tecnoglass (NYSE:TGLS) but has lowered the price target from $57 to $46.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:12 pm

SBRA

Stifel analyst Stephen Manaker maintains a 'Buy' rating on Sabra Health Care REIT (NASDAQ:SBRA) and raises the price target from $14 to $16.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:11 pm

O

Stifel analyst Simon Yarmak has maintained a 'Buy' rating on Realty Income (NYSE:O) but lowered the price target from $69.5 to $67.5.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:09 pm

NYXH

Stifel analyst Jonathan Block has maintained a 'Buy' rating on Nyxoah (NASDAQ:NYXH) but lowered the price target from $14 to $10.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:06 pm